Drug Trial Radar · NCT00203034
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
Last checked: Nov 20, 2026Latest source record: Mar 9, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
472
Actual
Start
May 2000
Primary completion
Jan 2003
Study completion Jan 2003
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
Conditions
- Parkinson's Disease
Interventions
rasagiline mesylateDrug
0.5 mg rasagiline mesylate oral once daily
1.0 mg rasagiline mesylateDrug
1.0 mg rasagiline mesylate oral once daily
PlaceboOther
oral placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the mean total daily "OFF" timeTime frame: 26 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Rush - Presbyterian St. Luke's Medical Center
Chicago, Illinois
Columbia - Presbyterian Medical Center
New York, New York
University of Rochester
Rochester, New York
Baylor College of Medicine
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.